Severe Arterial Hypertension from Cullin 3 Mutations Is Caused by Both Renal and Vascular Effects

Waed Abdel Khalek1,2, Chloé Rafael1,2,3,4,5, Irmine Loisel-Ferreira1,2

  • 1Institut National de la Santé et de la Recherche Médicale U970, Paris Cardiovascular Research Center, Paris, France.

Insights

Mutations in Cullin 3 (CUL3) cause severe familial hyperkalemic hypertension (FHHt) by impacting both kidney and blood vessel function. This study reveals CUL3 mutations activate RhoA, contributing to vascular dysfunction in FHHt.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Research
  • Nephrology

Background:

  • Familial hyperkalemic hypertension (FHHt) is a rare genetic disorder.
  • Mutations in WNK1, WNK4, KLHL3, or CUL3 genes cause FHHt.
  • CUL3 mutations, specifically exon 9 skipping, lead to a more severe FHHt phenotype.

Purpose of the Study:

  • To investigate the mechanisms by which CUL3 mutations cause severe hypertension.
  • To compare the effects of ubiquitous versus vascular smooth muscle-specific expression of mutant Cul3 (Cul3∆9).
  • To elucidate the roles of renal and vascular factors in CUL3-associated hypertension.

Main Methods:

  • Generated and compared two mouse models: ubiquitous (pgk-Cul3∆9) and vascular smooth muscle-specific (SM22-Cul3∆9) Cul3∆9 expression.
  • Performed pharmacologic studies on isolated aortas.
  • Created HEK293 cell lines overexpressing wild-type or mutant Cul3.
  • Analyzed blood pressure, electrolyte levels, gene expression, and protein abundance.

Main Results:

  • pgk-Cul3∆9 mice exhibited hypertension, hyperkalemia, hyperchloremia, and low renin.
  • SM22-Cul3∆9 mice showed increased blood pressure without significant renal transport changes.
  • Both models displayed altered aortic reactivity and amlodipine sensitivity.
  • Aortas from SM22-Cul3∆9 mice showed increased RhoA expression, linked to decreased ubiquitination in Cul3∆9 cells.

Conclusions:

  • CUL3 mutations induce severe hypertension through combined renal and vascular dysfunction.
  • Vascular dysfunction in CUL3-associated hypertension involves RhoA activation.
  • Understanding these mechanisms may inform therapeutic strategies for FHHt.
Abstract

Related Concept Videos

Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
587
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
452
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
480
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K